Literature DB >> 1601751

Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins.

R E Hancock1, F Bellido.   

Abstract

The fourth generation cephalosporins, cefpirome and cefepime, demonstrate better activity against strains of Enterobacter cloacae with derepressed beta-lactamase than the third generation compounds cefotaxime and ceftriaxone. Several methodological refinements were used to measure the parameters, predicted by the Zimmermann-Rosselet equation to be important in the efficacy of beta-lactams. Outer membrane permeability was measured by a novel HPLC method. The kinetics of interaction of purified beta-lactamase with beta-lactams were estimated to calculate the inhibition and catalytic constants. The periplasmic concentration of beta-lactams leading to growth inhibition of cells was determined by substituting the above parameters into the Zimmermann-Rosselet equation. Consideration of these three factors allowed accurate prediction of MICs in isogenic E. cloacae strains with differing porin or beta-lactamase contents. The fourth generation cephalosporins had markedly reduced affinity for beta-lactamase and increased outer membrane permeability when compared to the third generation cephalosporins. Such advantages were only partly offset by a lower stability of complexes with beta-lactamase and reduced affinity for their targets.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1601751     DOI: 10.1093/jac/29.suppl_a.1

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  31 in total

1.  Detection of extended-spectrum beta-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes.

Authors:  E Tzelepi; P Giakkoupi; D Sofianou; V Loukova; A Kemeroglou; A Tsakris
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  In vitro activity of cefpirome against selected clinical enterobacterial isolates with beta-lactamase-mediated resistance.

Authors:  L S Tzouvelekis; E Tzelepi; A F Mentis; N J Legakis
Journal:  Infection       Date:  1995 Nov-Dec       Impact factor: 3.553

3.  Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.

Authors:  J C Fung-Tomc; E Gradelski; E Huczko; T J Dougherty; R E Kessler; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.

Authors:  B Allaouchiche; D Breilh; H Jaumain; B Gaillard; S Renard; M C Saux
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 5.  A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World.

Authors:  Pranita D Tamma; Yohei Doi; Robert A Bonomo; J Kristie Johnson; Patricia J Simner
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

6.  Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams.

Authors:  G S Babini; M Yuan; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

7.  Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.

Authors:  R S Malone; D N Fish; E Abraham; I Teitelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 8.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

9.  Disposition kinetics and urinary excretion of cefpirome after intravenous injection in buffalo calves.

Authors:  Neetu Rajput; Vinod K Dumka; Harpal S Sandhu
Journal:  J Vet Sci       Date:  2007-03       Impact factor: 1.672

10.  Uptake of cefepime by phagocytosing polymorphonuclear neutrophils and subsequent intracellular killing.

Authors:  H Pruul; P J McDonald
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.